Cancer & Hematology Centers of Western Mi, P.C.
Cancer & Hematology Centers of Western Mi, P.C. was paid $59.56M by Medicaid between Jan 2018 and Dec 2024, across 147 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 28% of everything it billed.
33Billing provider infoCANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C.
GRAND RAPIDS, MI 49503
GRAND RAPIDS, MI 49503
33aNPI1528018389assigned 05/11/2006
33bProvider typeSpecialist
28Total paid$59.56M
24GClaims449,502
24DCodes billed147
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in Michigan
Rank by total paid#1 of 181
Median peer was paid$94K
This provider vs. median632×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 63,338 | $9.30M | |
| 2019 | 55,875 | $8.34M | |
| 2020 | 60,747 | $8.67M | |
| 2021 | 68,718 | $9.40M | |
| 2022 | 64,796 | $8.68M | |
| 2023 | 68,656 | $7.07M | |
| 2024incomplete | 67,372 | $8.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 28% | 2,325 | 1,768 | $16.87M |
| J9299 | Injection, nivolumab, 1 mg | 21% | 2,633 | 1,622 | $12.36M |
| J2505 | Injection, pegfilgrastim, 6 mg | 7.6% | 1,515 | 1,139 | $4.50M |
| J9173 | Injection, durvalumab, 10 mg | 3.5% | 468 | 304 | $2.09M |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 3.1% | 886 | 651 | $1.87M |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 3.1% | 839 | 527 | $1.87M |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 2.8% | 606 | 305 | $1.67M |
| J9306 | Injection, pertuzumab, 1 mg | 2.4% | 292 | 213 | $1.44M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.4% | 27,073 | 14,357 | $1.43M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.3% | 25,627 | 23,101 | $1.34M |
| J9035 | Injection, bevacizumab, 10 mg | 2.2% | 510 | 268 | $1.34M |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 1.5% | 565 | 306 | $872K |
135 more codes
| J1930 | Injection, lanreotide, 1 mg | 1.3% | 225 | $784K |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation agreement | 1.3% | 5,237 | $776K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 1.3% | 1,336 | $760K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | 1.3% | 13,648 | $759K |
| 99215 | Doctor's office visit, returning patient (complex) | 1.2% | 10,001 | $731K |
| 99223 | Prolong inpt eval add15 m | <1% | 4,512 | $434K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 10,147 | $424K |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 1,014 | $407K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 10,492 | $399K |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | <1% | 723 | $359K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | <1% | 244 | $312K |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | <1% | 75 | $302K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 3,525 | $284K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,810 | $282K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 50,721 | $275K |
| 96417 | <1% | 7,953 | $255K | |
| 80053 | Comprehensive metabolic panel | <1% | 33,774 | $250K |
| Q5112 | Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | <1% | 116 | $250K |
| 96416 | <1% | 4,356 | $248K | |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 239 | $190K |
| 99205 | Prolong outpt/office vis | <1% | 1,628 | $168K |
| J1437 | Injection, ferric derisomaltose, 10 mg | <1% | 120 | $168K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 3,695 | $147K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,688 | $140K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 3,703 | $137K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | <1% | 44 | $135K |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | <1% | 19 | $124K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,365 | $118K |
| 96401 | <1% | 3,407 | $109K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 507 | $107K |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,520 | $104K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 1,905 | $103K |
| 96415 | <1% | 6,383 | $103K | |
| 96411 | <1% | 3,221 | $95K | |
| 96367 | <1% | 5,851 | $94K | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 331 | $87K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 4,755 | $65K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 266 | $63K |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 2,242 | $56K |
| J9206 | Injection, irinotecan, 20 mg | <1% | 1,835 | $51K |
| J0897 | Injection, denosumab, 1 mg | <1% | 27 | $51K |
| 82728 | <1% | 5,021 | $51K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 1,944 | $51K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,449 | $49K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,112 | $48K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,105 | $48K |
| 99245 | <1% | 402 | $47K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 2,625 | $46K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 2,913 | $39K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,214 | $39K |
| 96402 | <1% | 2,484 | $39K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 394 | $39K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,707 | $36K |
| J9171 | Injection, docetaxel, 1 mg | <1% | 322 | $33K |
| 84466 | <1% | 3,447 | $32K | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 1,064 | $29K |
| 83735 | <1% | 5,808 | $26K | |
| 96368 | <1% | 2,677 | $25K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 119 | $24K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 415 | $24K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,483 | $23K |
| 82024 | <1% | 1,030 | $23K | |
| J9071 | Injection, cyclophosphamide (auromedics), 5 mg | <1% | 47 | $23K |
| 83615 | <1% | 5,510 | $23K | |
| 36430 | <1% | 1,301 | $19K | |
| 99195 | <1% | 398 | $19K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 109 | $18K |
| 96409 | <1% | 491 | $18K | |
| 83540 | <1% | 3,811 | $18K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16,898 | $18K |
| 82607 | <1% | 1,731 | $17K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 116 | $15K |
| 82746 | <1% | 1,389 | $15K | |
| 82378 | <1% | 1,005 | $14K | |
| 86300 | <1% | 796 | $13K | |
| 85055 | <1% | 670 | $11K | |
| 82784 | <1% | 674 | $11K | |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 529 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,396 | $10K |
| 82533 | <1% | 993 | $9K | |
| 83521 | <1% | 474 | $9K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 287 | $8K |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 721 | $8K |
| 96523 | <1% | 652 | $8K | |
| 85610 | <1% | 2,568 | $8K | |
| J9075 | Injection, cyclophosphamide, not otherwise specified, 5 mg | <1% | 46 | $8K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 108 | $7K |
| 96377 | <1% | 792 | $6K | |
| 84165 | <1% | 922 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 313 | $6K |
| 86704 | <1% | 662 | $6K | |
| 87340 | <1% | 696 | $5K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 68 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,396 | $4K |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 1,447 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 153 | $4K |
| J3490 | Unclassified drugs | <1% | 3,387 | $3K |
| 86706 | <1% | 453 | $3K | |
| 85046 | <1% | 782 | $3K | |
| G9001 | Coordinated care fee, initial rate | <1% | 69 | $3K |
| 38222 | <1% | 38 | $3K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 1,094 | $3K |
| 85730 | <1% | 629 | $3K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 64 | $3K |
| 84100 | <1% | 859 | $2K | |
| J9181 | Injection, etoposide, 10 mg | <1% | 244 | $2K |
| 84439 | <1% | 347 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,646 | $2K |
| 81000 | <1% | 667 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,493 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 154 | $2K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,432 | $2K |
| 84550 | <1% | 495 | $2K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 74 | $1K |
| G9002 | Coordinated care fee, maintenance rate | <1% | 60 | $1K |
| 36593 | <1% | 85 | $1K | |
| 84703 | <1% | 200 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 157 | $1K |
| 85651 | <1% | 223 | $721.86 | |
| 84156 | <1% | 359 | $636.49 | |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 138 | $582.38 |
| 99442 | <1% | 45 | $530.94 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 60 | $423.62 |
| 82565 | <1% | 107 | $352.58 | |
| 99441 | <1% | 40 | $266.89 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 125 | $251.02 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 462 | $248.98 |
| 83883 | <1% | 415 | $233.68 | |
| 86140 | <1% | 41 | $173.51 | |
| 86301 | <1% | 14 | $159.95 | |
| 83010 | <1% | 13 | $116.10 | |
| 82550 | <1% | 24 | $109.24 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 46 | $48.34 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17 | $47.70 |
| S0028 | Injection, famotidine, 20 mg | <1% | 41 | $0.84 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGENSCHAW, STUART (EXECUTIVE DIRECTOR)